AI-generated analysis. Always verify with the original filing.
Calidi Biotherapeutics, Inc. entered into a material definitive agreement in connection with terms of outstanding common warrants (Existing Warrants), involving unregistered sales of equity securities and pre-funded warrants. The Company issued a press release on March 5, 2026 announcing the launch of the Offering, with related exhibits including the Underwriting Agreement dated March 6, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
above, in connection with the terms of certain of our outstanding common warrants to purchase shares of Common Stock (the “Existing Warrants”). As originally is
Unregistered Sales of Equity Securities. Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference.
Other Events. On March 5, 2026, the Company issued a press release announcing the launch of the Offering. A copy of the press release is furnished as Exhibit 99
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated March 6, 2026 4.1 Form of Pre-funded Warrant 4.2 Form